The record of the 27 November meeting of the Working Group on AIDS described it as having gone "reasonable [sic] well"; whereas other reports expressed a significantly different viewpoint. Read more about The record of the 27 November meeting of the Working Group on AIDS described it as having gone "reasonable [sic] well"; whereas other reports expressed a significantly different viewpoint.
The CBLA announced that they planned to heat all Factor 8 manufactured at BPL/PFL from April 1985. Read more about The CBLA announced that they planned to heat all Factor 8 manufactured at BPL/PFL from April 1985.
Dr Jones wrote to colleagues enclosing a copy of his conference paper and explaining his decision to present the information about possible seroconversions at the conference. Read more about Dr Jones wrote to colleagues enclosing a copy of his conference paper and explaining his decision to present the information about possible seroconversions at the conference.
The Biologicals Sub-Committee of the Committee on Safety of Medicines decided that there was "insufficient evidence for action to be taken on any specific product" but that "close surveillance should be maintained on the two possible cases of HTLV-III transmission in recipients of Armour material." Read more about The Biologicals Sub-Committee of the Committee on Safety of Medicines decided that there was "insufficient evidence for action to be taken on any specific product" but that "close surveillance should be maintained on the two possible cases of HTLV-III transmission in recipients of Armour material."
EAGA's discussion of cases found the Lewisham patient (referred to in the minutes as the patient with mild haemophilia who had not received treatment since 1980) could not be explained by late seroconversion. Read more about EAGA's discussion of cases found the Lewisham patient (referred to in the minutes as the patient with mild haemophilia who had not received treatment since 1980) could not be explained by late seroconversion.
The meetings of the AIDS group of UKHCDO directors agreed to recommend that only heat-treated product should be used thereafter. Read more about The meetings of the AIDS group of UKHCDO directors agreed to recommend that only heat-treated product should be used thereafter.
Professor Bloom was assured by the DHSS that prompting "the appropriate manufacturers" to apply for abridged product licences to ensure the supply of heat-treated product was a "high priority item". Read more about Professor Bloom was assured by the DHSS that prompting "the appropriate manufacturers" to apply for abridged product licences to ensure the supply of heat-treated product was a "high priority item".
Professor Arthur Bloom wrote to the DHSS to urge that heat-treated products be licensed so as to be freely available. Read more about Professor Arthur Bloom wrote to the DHSS to urge that heat-treated products be licensed so as to be freely available.
Gilbert C et al published an article in "The Lancet" describing a case of seroconversion of AIDS in a person with mild haemophilia after administration of high doses of heat treated Factor 8 concentrate. Read more about Gilbert C et al published an article in "The Lancet" describing a case of seroconversion of AIDS in a person with mild haemophilia after administration of high doses of heat treated Factor 8 concentrate.
In a paper on the safety of heat-treated Factor 8 prepared by Dr Rotblat, it was reported there were two cases of seroconversion after treatment with heat-treated Factorate from a batch known to contain a donor who had AIDS. Read more about In a paper on the safety of heat-treated Factor 8 prepared by Dr Rotblat, it was reported there were two cases of seroconversion after treatment with heat-treated Factorate from a batch known to contain a donor who had AIDS.